Industry News

ProtoKinetix, Incorporated is pleased to provide the following corporate update to its stockholders:. The management team has been very busy since our last update. The following is a summary of our strategy and action in support of the Company’ s direction."/>
ProtoKinetix’ 2nd Quarter Scientific Update
True Nature Holding, Inc. today updated its shareholders by announcing that it has progressed on its acquisition strategy, consolidating a leadership position in the Compounding Pharmacy space. "Over the last month we have advanced the due diligence and integration plan for the first phase of pharmacy acquisitions as well as started to build out our management team," said Jim Driscoll, the CEO of True Nature Holding, Inc. The following is a summary of the key..."/>
True Nature Holding, Inc. Receives Georgia Board of Pharmacy Approval on Integrity Acquistion, Updates Acquisition Timing and Appoints Executive
Acadia Healthcare Company, Inc.. The CMA, which is the United Kingdom’ s primary competition and consumer authority, announced that the acquisition of Priory by Acadia will be referred for a Phase 2 investigation, unless Acadia and Priory are able to offer undertakings that..."/>
Update on the U.K.’S Competition and Markets Authority’s Review of Acadia Healthcare’s Acquisition of Priory Group
Exactech, Inc., a developer and producer of bone and joint restoration products for extremities, knee, hip, spine and biologics, will release its second quarter financial results after the market closes on Monday, August 1, 2016. A copy of the earnings release will be available at http://www.hawkassociates.com. The company will hold a conference call with CEO David Petty and key members of the management team on Tuesday, August 2nd at 10:00 a.m. Eastern Time."/>
Exactech Schedules Second Quarter 2016 Earnings Release and Conference Call
Alexion Pharmaceuticals, Inc. announced today that researchers presented new data from an ongoing open-label, Phase 1/ 2 trial of intravenous SBC-103, an investigational enzyme replacement therapy, in children with..."/>
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB)
Ligand Pharmaceuticals Incorporated announced today plans to report second quarter 2016 financial results on August 4, 2016. Ligand’ s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call. About Ligand Pharmaceuticals Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines."/>
Ligand to Report Second Quarter Results on August 4th
AngioSoma, Inc., previously known as First Titan Corp., changed our corporate name and focus to that of a clinical stage biopharmaceutical company introducing an exciting new treatment for one of the world's most insidious and pervasive diseases, peripheral artery disease. The introduction of this new drug, Liprostin™, a liposomal controlled release encapsulation of ProstaglandinE1, will greatly improve the effectiveness of the drug and of current..."/>
AngioSoma's Corporate Focus
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’ s disease and diabetes, today announced that the Company will deliver an oral presentation on its lead product..."/>
VTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer’s Association International Conference
Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, announced today that the Company will release its financial results for the second quarter ended June 30, 2016, after the close of the stock market on Wednesday, July 27, 2016.. Merit will hold its investor conference call on the same day at 5:00 p.m. Eastern. The domestic telephone number is..."/>
Merit Medical Systems to Announce Second Quarter Results on July 27, 2016
PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ®, today announced that the U.S. Patent and Trademark Office has granted patent protection of the Melligen cells that are a part of PharmaCyte’ s therapy for Type 1 and insulin-dependent Type 2 diabetes.. The Melligen cells are human cells that have been..."/>
PharmaCyte Biotech Receives Patent Protection of the Melligen Cells to Treat Diabetes
OncoMed Pharmaceuticals, a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics. Using Guardant Health's digital sequencing technology, the companies have developed a custom blood test that looks for specific biomarkers relevant to OncoMed's ongoing Phase 1 a/1b trial of its..."/>
Guardant Health Collaborates with OncoMed Pharmaceuticals on Anti-RSPO3 Clinical Trial
Paddy Power Betfair shares ticked up 1.6 pc, or 135 p to 8610 p yesterday, William Hill moved forward 0.7 pc, or 1.9 p to 271.2 p, while Ladbrokes leapt 3.1 pc, or 3.7 p to 123.7 p."/>
Daily Mail, London, market report column [Daily Mail, London]
Valeant Pharmaceuticals International, Inc. today commented on recent stock transactions made by Valeant's former chief executive officer, J. Michael Pearson. The Company understands that Mr. Pearson exercised and sold options representing approximately 4.4 million shares, which would expire within the next 12 months, and sold approximately 411,000 shares of common stock in June and July to satisfy tax obligations with respect to the 2015..."/>
Valeant Pharmaceuticals Comments On Recent Stock Transactions
Valeant Pharmaceuticals International, Inc. today commented on recent stock transactions made by Valeant's former chief executive officer, J. Michael Pearson. The Company understands that Mr. Pearson exercised and sold options representing approximately 4.4 million shares, which would expire within the next 12 months, and sold approximately 411,000 shares of common stock in June and July to satisfy tax obligations with respect to the..."/>
Valeant Pharmaceuticals Comments On Recent Stock Transactions
Windtree Therapeutics, Inc., a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has received the third $1.0 million tranche under a previously announced Phase II Small Business Innovation Research grant valued at up to $3.0 million to support continued development of the company's aerosolized KL4 surfactant as a potential medical countermeasure..."/>
Windtree Awarded $1.0 million SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury
Waters Corporation announced VICAM ®, a Waters ® Business, received the 2016 North American Food Safety Diagnostics Market Leadership Award from Frost& Sullivan. This Smart News Release features multimedia."/>
VICAM, a Waters Business, Receives 2016 North American Food Safety Diagnostics Market Leadership Award from Frost & Sullivan
Spotlight Innovation Inc. announced today that Geoffrey Laff, Ph.D., has joined the company in the new position of Vice President of Scientific Strategy. Laff will oversee the development and implementation of Spotlight Innovation's scientific research and development strategy, assist in the exploration and analysis of new acquisition opportunities, and contribute to clinical management activities. Laff is a life sciences industry veteran..."/>
Spotlight Innovation Appoints Dr. Geoffrey Laff as Vice President of Scientific Strategy
West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, today announced that it will release second quarter 2016 financial results before the market opens on Thursday, July 28, 2016, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call please dial 877-930-8295 or 253-336-8738."/>
West to Host Second Quarter 2016 Conference Call
Castlight Health indicates that only 47 percent of hospitals reporting..."/>
Majority of U.S. Hospitals Still Fail to Implement ICU Policies Known to Dramatically Lower Patient Death Rates
PositiveID Corporation, is scheduled to present at RedChip’ s Small Stocks, Big Money Investor Conference on Thursday, July 21, 2016, at 11:30 a.m. ET. The presentation can be viewed at www.RedChip.com. A live Q&A session will follow the investor presentation.."/>
PositiveID Corporation to Present at RedChip’s Small Stocks, Big Money Investor Conference
Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based..."/>
Argos Therapeutics Announces First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in the Treatment of HIV
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 4, at 4:30 p.m. ET to discuss second quarter 2016 financial results and provide a general business update.. Dial-in Number U.S./ Canada Dial-in Number: 303-6313 International Dial-in Number: 813-4734 Conference ID: 40166552. Replay Dial-in Number: 859-2056 Replay..."/>
BioMarin to Host Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4 at 4:30pm ET
MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the Proceedings of the National Academy of Sciences of the United States of America. The article is the first to examine data from SHaRe, or the Sarcomeric Human Cardiomyopathy Registry, and demonstrates the power of combining..."/>
SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials851 Articles
Information Technology749 Articles
Consumer Discretionary706 Articles
Industrials544 Articles
Health Care467 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.